Published
Video duration:
2 min
Health: Danish giant Novo Nordisk sets up in France
Emmanuel Macron will go to Chartres on Thursday, November 23 to reveal the amount that Novo Nordisk intends to invest in a factory. Its sales are exploding, and its turnover has allowed Denmark to avoid recession. The secret: its diabetes medication that America uses as an appetite suppressant. – (France 2)
Emmanuel Macron will go to Chartres on Thursday, November 23 to reveal the amount that Novo Nordisk intends to invest in a factory. Its sales are exploding, and its turnover has allowed Denmark to avoid recession. The secret: its diabetes medication that America uses as an appetite suppressant.
You may not know the name, but Novo Nordisk, which makes Ozempic, has become a giant in the pharmaceutical industry. Last year, the Danish firm became the largest stock market value in Europe, with 420 billion euros, far ahead of LVMH, and the GDP of Denmark. Growing demand is pushing the company to invest in a French factory in Chartres (Eure-et-Loir).
The factory which manufactures insulin injector pens already employs 1,600 people. Novo Nordisk has decided to build on it with a massive investment, which should be the largest in recent years in the health sector in France. The country was preferred over other sites in the group. Right next door, an SME produces spare parts for Novo Nordisk which represent nearly 20% of its turnover.
Treatments that are debated
The use of the pharmaceutical giant’s diabetes treatments is debated. On social networks, many Internet users sell its merits as an appetite suppressant. Its new product against obesity could soon be marketed in France. The market is growing at the moment. In France, Novo Nordisk treatments are prescribed only by prescription.
